title: Intravenous rituximab for the treatment of cancer-associated retinopathy.
authors.forename: Chris
authors.initials: C
authors.lastname: Or
authors.forename: David R
authors.initials: DR
authors.lastname: Collins
authors.forename: Andrew B
authors.initials: AB
authors.lastname: Merkur
authors.forename: Yujuan
authors.initials: Y
authors.lastname: Wang
authors.forename: Chi-Chao
authors.initials: CC
authors.lastname: Chan
authors.forename: Farzin
authors.initials: F
authors.lastname: Forooghian
mesh_terms: D000236:Adenoma / Q000150:complications / Q000473:pathology; D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000473:pathology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D059545:Paraneoplastic Syndromes, Ocular / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D000069283:Rituximab; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab